betamethasone valerate 0.1% cream

DRUG7 trials

Sponsors

Shahid Beheshti University of Medical Sciences, Sheffield Teaching Hospitals NHS Foundation Trust, Assiut University, Cairo University, Queen Mary Hospital, Hong Kong

Conditions

ALK-TKIAlopecia AreataAtopic Eczema/Dermatitis (Non-Specific)Discoid Lupus ErythematosusEGFR-TKILichen Simplex ChronicusParonychiaPsoriasis

Phase 1

Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.

Assiut UniversityAlopecia Areata

Start: 2023-10-31End: 2024-10-31Target: 60Updated: 2023-10-18

Phase 2

Skin bioMARkers for Atopic Eczema Therapy Evaluation

CompletedNCT04194814

Sheffield Teaching Hospitals NHS Foundation TrustAtopic Eczema/Dermatitis (Non-Specific)

Start: 2020-11-20End: 2021-09-30Updated: 2025-07-18

Phase 3

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

RecruitingNCT06643416

Queen Mary Hospital, Hong KongALK-TKI, EGFR-TKI, Paronychia

Start: 2024-10-09End: 2025-12-31Target: 40Updated: 2024-10-18

Phase 4

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

RecruitingNCT07508124

Baylor College of MedicineUrinary Tract Infection

Start: 2026-05-08End: 2027-12-01Target: 40Updated: 2026-08-07

Unknown Phase

Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus

CompletedNCT00608673

Shahid Beheshti University of Medical SciencesDiscoid Lupus Erythematosus

Start: 2006-04-30End: 2007-11-30Updated: 2008-02-15

Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus

Not yet recruitingNCT06267066

Cairo UniversityLichen Simplex Chronicus

Start: 2024-03-01End: 2024-08-30Target: 60Updated: 2024-02-20

Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis

Not yet recruitingNCT07366268

Assiut UniversityPsoriasis

Start: 2026-05-01End: 2028-03-01Target: 36Updated: 2026-03-03

Related Papers

Novel biophysical skin biomarkers discriminate topical anti‐inflammatory treatments based on their potential for local adverse effects

JEADV Clinical Practice2024-09-091 citations